natgillin/translations-raw huggingface dataset:
The integrated circuit s according to claim 1, wherein the portion of the bits necessary to indicate the allocated plurality of clusters are LSBs (Least Significant Bits) of the resource allocation information. 
Uređaj za prijenos prema zahtjevu 1, naznačen time da su dio bitova potrebnih za označavanje dodijeljenog pluraliteta klastera LSB-ovi, Najmanje Bitni Bitovi, podatka o dodjeli resursa.
The integrated circuit according to claim 1, wherein the remaining bit(s) are MSBs (Most Significant Bits) of the resource allocation information, and the defined value is zero. 
Uređaj za prijenos prema zahtjevu 1 ili 2, naznačen time da su preostali bit(ovi) MSB-ovi, NajBitniji Bitovi, podatka o dodjeli resursa, a definirana vrijednost je nula.
The integrated circuit according to claim 10, wherein the remaining bit(s) are MSBs (Most Significant Bits) of the resource allocation information, and the defined value is zero. 
Postupak prijenosa prema zahtjevu 9 ili 10, naznačen time da su preostali bit(ovi) MSB-i, NajBitniji Bitovi, podatka o dodjeli resursa, a definirana vrijednost je nula.
A monoclonal antibody, or a divalent functional fragment thereof, capable of inhibiting the c-Met dimerization, said antibody or a divalent functional fragment thereof, comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 with respectively the amino acid sequences SEQ ID Nos. 
Monoklonalno antitijelo, ili njegov dvovalentni funkcionalni fragment, koji može inhibirati dimerizaciju c-Met, rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, sadrži teški lanac koji sadrži CDR-H1, CDR-H2 te CDR-H3 s aminokiselinskim sekvencijama SEQ ID Nos.
5, 6 and 7, said antibody or a divalent functional fragment thereof, being further characterized in that: 
5, 6 i 7, rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, dalje naznačeno time da:
28 and ii) said antibody or a divalent functional fragment thereof, is coupled chemically to a cytotoxic agent. 
28 i ii) rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, vezan je kemijski za citotoksično sredstvo.
The antibody or divalent functional fragment thereof of claims 1 to 4, characterized in that said cytotoxic agent is a mitotic inhibitor. 
Antitijelo ili njegov dvovalentni funkcionalni fragment iz patentnih zahtjeva 1 do 4, naznačeno time da je rečeno citotoksično sredstvo mitotički inhibitor.
The antibody or divalent functional fragment thereof of claims 1 to 6, for use as a medicament. 
Antitijelo ili njegov dvovalentni funkcionalni fragment iz patentnih zahtjeva 1 do 6, za upotrebu kao lijek.
The antibody or the composition for use according to claim 11, characterized in that said cancer is a cancer chosen from prostate cancer, osteosarcomas, lung cancer, breast cancer, endometrial cancer, glioblastoma or colon cancer. 
Antitijelo ili pripravak za upotrebu prema patentnom zahtjevu 11, naznačeno time da rečeni karcinom jest karcinom odabran od karcinoma prostate, osteosarkoma, karcinoma pluća, karcinoma dojke, karcinoma endometrija, glioblastoma ili karcinoma debelog crijeva.
The co-crystal of claim 1, wherein a molar ratio of adipic acid to the compound of formula I is about 1 to 2. 
Sukristal u skladu s patentnim zahtjevom 1, naznačen time što je molarni omjer između adipinske kiseline i spoja formule I otprilike 1 do 2.
having a DSC peak in its DSC thermogram at about 195 °C and about 245 °C. 
ima maksimum DSC u svom DSC termogramu na otprilike 195 °C i otprilike 245 °C.
potentiating a therapeutic regimen for the treatment of cancer in a patient; or 
potenciranju terapijskog režima u liječenju raka kod pacijenta; ili
treating cancer in a patient. 
liječenju raka kod pacijenta.
A process for the production of a snack comprising a soft pastry bakery product in the form of an oblong bread roll, filled with a chocolate layer in the form of a slab, that comprises the steps of: 
Postupak za proizvodnju užine koja sadrži pekarski proizvod u vidu mekog peciva u obliku duguljaste žemlje, napunjene slojem čokolade u obliku ploče, koji obuhvaća korake:
making available a semifinished product in the form of an oblong bread roll, obtained from a flour-based dough, leavened with natural yeast, 
osiguravanja polugotovog proizvoda u obliku duguljaste žemlje, dobivene od tijesta na bazi brašna, koje je naraslo pomoću prirodnog kvasca,
baking said semifinished product, obtaining a bakery product in the form of an oblong bread roll having a moisture content comprised between 22% and 24% by weight of the total weight of said bakery product, 
pečenja navedenog polugotovog proizvoda, čime se dobiva pekarski proizvod u obliku duguljaste žemlje koji ima sadržaj vlage sadržan između 22% i 24% po težini od ukupne težine navedenog pekarskog proizvoda,
injecting a hydro-alcoholic solution into said bakery product, while it is still warm, in such a quantity as to bring the moisture content of said bakery product to a value comprised between 30% and 33% by weight of its total weight, 
ubrizgavanja hidroalkoholne otopine u navedeni pekarski proizvod, dok je još topao, u količini koja dovodi sadržaj vlage u spomenutom pekarskom proizvodu na vrijednost sadržanu između 30% i 33% po težini njegove ukupne težine,
depositing a layer of melted chocolate onto the upper surface of said lower portion. 
nanošenja sloja otopljene čokolade na gornju površinu navedenog donjeg dijela.
The process according to claim 1, wherein said bakery product obtained by baking in said step b) has a value of Aw equal to 0.81-0.85 and, following said step c) of injecting said hydro-alcoholic solution, a value of Aw equal to 0.85-0.89. 
Postupak prema patentnom zahtjevu 1, naznačen time što navedeni pekarski proizvod dobiven pečenjem u navedenom koraku b) ima vrijednost Aw jednaku 0.81-0.85 i, nakon navedenog koraka c) ubrizgavanja navedene hidroalkoholne otopine, vrijednost Aw jednaku 0.85-0.89.
The process according to any one of claims 1 to 8, wherein said longitudinal cut is carried out after cooling the bakery product, said cooling occurring after the aforementioned injection step c). 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time što se navedeno uzdužno zarezivanje izvodi poslije hlađenja pekarskog proizvoda, navedeno hlađenje se odvija poslije prethodno spomenutog koraka c) ubrizgavanja.
The process according to any one of claims 1 to 10, wherein said step c) of injecting a hydro-alcoholic solution is carried out by means of the insertion of a plurality of injectors into the bakery product, on its upper surface, said injectors being vertically inserted top-down to a level comprised between 5/10ths and 9/10ths of the height (h) of the bakery product. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time što se navedeni korak c) ubrizgavanja hidroalkoholne otopine izvodi pomoću ubacivanja nekoliko injektora u pekarski proizvod, na njegovoj gornjoj površini, pri čemu se navedeni injektori ubacuju vertikalno odozgo prema dolje do razine sadržane između pet desetina i devet desetina visine (h) pekarskog proizvoda.
The process according to claim 1, wherein, in said deposition step e), said melted chocolate is dispensed through a dispenser nozzle, comprising at least one hole, and deposited in the form of at least one strip on the upper surface of the lower portion of the bakery product. 
Postupak prema patentnom zahtjevu 1, naznačen time što, u navedenom koraku e) nanošenja, navedena otopljena čokolada se raspodjeljuje kroz mlaznicu za doziranje, koja sadrži najmanje jednu rupu, i nanosi se u obliku najmanje jedne trake na gornju površinu donjeg dijela pekarskog proizvoda.
The process according to claim 19, wherein, in said depositing step e), said melted chocolate is dispensed through a dispenser nozzle, comprising at least two holes suitable spaced from each other, and deposited in the form of two strips onto the upper surface of the lower portion of the bakery product, said strips undergoing widening sufficient for them to come into contact with one another to create a continuous chocolate layer, but not to cause spilling of the chocolate beyond the edges of the deposition surface. 
Postupak prema patentnom zahtjevu 19, naznačen time što, u navedenom koraku e) nanošenja, navedena otopljena čokolada se raspodjeljuje kroz mlaznicu za doziranje, koja sadrži najmanje dvije rupe prikladno razmaknute jedna od druge, i nanosi se u obliku dvije trake na gornju površinu donjeg dijela pekarskog proizvoda, navedene trake se proširuju dovoljno da dođu u kontakt jedna s drugom da bi stvorile kontinuirani sloj čokolade, ali da ne dovedu do prelijevanja čokolade preko rubova površine na koju je nanesena.
A pharmaceutical composition comprising paroxetine or a pharmaceutically acceptable salt thereof for use in treating hot flashes associated with hormonal changes due to menopause, whereby the paroxetine composition is to be administered at an amount of 7.5 mg/day based on the paroxetine moiety, with the exception of nasal administration. 
Farmaceutski pripravak koji sadrži paroksetin ili njegovu farmaceutski prihvatljivu sol za uporabu u liječenju valunga koji su povezani s hormonalnim poremećajima uslijed menopauze, naznačen time da se pripravak paroksetina treba primjenjivati u količini od 7.5 mg/dan ovisno o udjelu paroksetina, s iznimkom nazalne primjene.
in said extrusion head (2) the simultaneous extrusion of the formed second mixture with the first mixture so that the polymer at least partially encloses the said particles; 
– u navedenoj ekstruzijskoj glavi (2) istodobnog ekstrudiranja dobivene druge smjese s prvom smjesom, tako da polimer u najmanju ruku djelomično oblaže navedene čestice;
whereby, on the basis of the formed second mixture, a first layer (4) is formed on the plastic strand (3), which first layer shall at least partially cover the outer surface of this plastic strand (3). 
gdje se, na osnovi dobivene druge smjese, načini prvi sloj (4) na plastičnoj niti (3), gdje će navedeni prvi sloj u najmanju ruku djelomično pokriti vanjsku površinu te plastične niti (3).
Method according to Claim 2, characterized in that, during cooling, gas bubbles are provided on at least a part of the outer surface of the plastic strand (3), which gas bubbles at irregular locations insulate the surface of the plastic strand (3) from the cooling medium (4), whereby the plastic strand (3) on its outer surface is at least partially provided with changes in the surface structure. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se, tijekom hlađenja, pušta mjehuriće plina po u najmanju ruku dijelu vanjske površine plastične niti (3), gdje navedeni mjehurići plina na nepravilnim mjestima izoliraju površinu plastične niti (3) od rashladnog medija (4), gdje plastična nit (3) na svojoj vanjskoj površini u najmanju ruku djelomično ima promijenjenu strukturu površine.
Method according to Claim 2 or 3, characterized in that the said cooling medium is water and in that the said gas bubbles are air and/or nitrogen bubbles. 
Postupak u skladu s patentnim zahtjevom 2 ili 3, naznačen time što je navedeni rashladni medij voda, te što su navedeni mjehurići plina mjehurići zraka i/ili dušika.
A nucleic acid molecule according to claim 1, wherein the encoded polypeptide further comprises a leader sequence. 
Molekula nukleinske kiseline prema zahtjevu 1, naznačena time što kodirani polipeptid nadalje sadrži vodeću sekvencu.
A nucleic acid molecule according to claim 3, wherein the encoded polypeptide comprises HPV16 E2 protein that has a deletion or mutation in its DNA binding domain. 
Molekula nukleinske kiseline prema zahtjevu 3, naznačena time što kodirani polipeptid sadrži HPV16 E2 protein koji ima deleciju ili mutaciju u svojoj DNA veznoj domeni.
A nucleic acid molecule according to claim 4, wherein the encoded polypeptide comprises SEQ ID NO: 3 or SEQ ID NO: 5. 
Molekula nukleinske kiseline prema zahtjevu 4, naznačena time što kodirani polipeptid sadrži SEQ ID NO: 3 ili SEQ ID NO: 5.
A nucleic acid molecule according to any one of the preceding claims, wherein the nucleic acid sequence is codon-optimized. 
Molekula nukleinske kiseline prema bilo kojem od prethodnih zahtjeva, naznačena time što je sekvenca nukleinske kiseline kodon optimizirana.
A vaccine composition according to claim 12 for use in inducing an immune response against HPV in a subject. 
Pripravak cjepiva prema zahtjevu 12 naznačen time što se koristi za induciranje kod subjekta imunološkog odgovora protiv HPV.
A vaccine composition according to claim 12 for use in a prime-boost vaccination to induce an immune response against HPV in a subject, wherein in a priming vaccine the vector is an adenoviral vector and in the boosting vaccine the vector is an MVA vector, or vice versa. 
Pripravak cjepiva prema zahtjevu 12 koji se koristi za primjenu u cijepljenju s primarnim pojačavanjem radi induciranja imunološkog odgovora protiv HPV-a kod subjekta, naznačen time što je vektor u primarnom cjepivu adenovirusni vektor i u booster cjepivu vektor je MVA vektor, ili obrnuto.
a first feed for biomass material or other organic material connecting to the upper zone of this reactor space; 
prvi dovod materijala biomase ili drugog organskog materijala koji se spaja na gornju zonu ovog reaktorskog prostora;
a second feed for heated heat carrier material, for instance sand, connecting to the upper side of this reactor space; 
drugi dovod za grijani materijal nosača topline, na primjer pijesak, koji se spaja na gornju stranu ovog reaktorskog prostora;
a first discharge for pyrolysis gas connecting to the upper zone of this reactor space at a distance from the first feed; and a second discharge for solid material, for instance carbon and heat carrier material, connecting to the underside of this reactor space; wherein 
prvi ispust za plin za pirolizu koji se spaja na gornju zonu ovog reaktorskog prostora na udaljenosti od prvog dovoda; i drugi ispust za kruti materijal, na primjer za ugljik i materijal nosača topline, koji se spaja na donju stranu ovog reaktorskog prostora;
a mechanical mixer is present in the reactor space for the purpose of mixing the incoming flow of biomass material with the incoming flow of preheated heat carrier material, characterized in that the maximum average velocity v of the pyrolysis gas and the thereby entrained material in the reactor space downstream of the mixer at a temperature in the range of 400°C - 550°C is about as great as the terminal falling velocity, such that at least a substantial separation between the discharge flows of respectively pyrolysis gas and solid material takes place predominantly under the influence of gravitational force, in particular without interposing of a cyclone. 
pri čemu reaktorski prostor je modeliran tako da je blokirano izravno strujanje od prvog dovoda i drugog dovoda do prvog ispusta; i mehanička miješalica je prisutna u reaktorskom prostoru u svrhu miješanja ulaznog strujanja materijala biomase s dolaznim strujanjem predgrijanog materijala nosača topline, naznačena time što je maksimalna prosječna brzina v plina za pirolizu i time zahvaćenog materijala u reaktorskom prostoru nizvodno od miješalice na temperaturi u rasponu od 400°C - 550°C približno jednako velika kao krajnja brzina pada, tako da se najmanje značajno razdvajanje između ispusnih strujanja odgovarajućeg plina za pirolizu i krutog materijala, odvija uglavnom pod djelovanjem gravitacijske sile, naročito bez umetanja ciklona.
Use of a device for subjecting biomass to pyrolysis as claimed in any of the foregoing claims, wherein an at least more or less vertical baffle is situated in the reactor space which connects to the upper wall of the reactor space, whereby the flow from the mixer, comprising a mixture of pyrolysis gas and solid material, and/or the part-flows of pyrolysis gas and solid material can only reach respectively the first discharge and the second discharge by passing over the lower edge of the baffle. 
Upotreba uređaja za podvrgavanje biomase pirolizi prema bilo kojem od prethodnih zahtjeva, naznačena time što se u reaktorskom prostoru nalazi najmanje više ili manje okomita pregrada koja se spaja na gornju stjenku reaktorskog prostora, pri čemu struja iz miješalice, koja sadrži mješavinu plina za pirolizu i krutog materijala, i/ili dijelovi strujanja plina za pirolizu i čvrstog materijala mogu samo doseći odgovarajući prvi ispust i drugi ispust prolazom preko donjeg ruba pregrade.
selecting a CHO cell transfected in (v) by selected growth in cultivation medium containing said first eukaryotic selection agent to which the first transfection vector confers resistance and said second eukaryotic selection agent to which the second transfection vector confers resistance and said third eukaryotic selection agent to which the third transfection vector confers resistance, 
selekcija CHO stanice transficirane u (v) za odabrani rast u mediju za uzgoj koji sadrži spomenuti prvi eukariotski selekcijski agens, na kojega prvi vektor za transfekciju prenosi otpornost i spomenuti drugi eukariotski selekcijski agens na kojega drugi vektor za transfekciju prenosi otpornost te spomenuti treći eukariotski selekcijski agens na kojega treći vektor za transfekciju prenosi otpornost,
cultivating said transfected CHO cell in a medium in the presence of said first and said second and said third eukaryotic selection agent, under conditions suitable for the expression of said first, second, and/or third nucleic acid, 
kultiviranje spomenute transficirane CHO stanice u mediju u prisutnosti spomenutog prvog, drugog i trećeg eukariotskog selekcijskog agensa, pod uvjetima pogodnima za ekspresiju spomenute prve, druge i/ili treće nukleinske kiseline,
recovering said secreted heterologous immunoglobulin from the cultivation medium and thereby producing a heterologous immunoglobulin in a CHO cell which is secreted to the cultivation medium, wherein the first, second, and third transfection vector each differ only in the nucleic acid conferring resistance to said first, second, and third eukaryotic selection agent. 
obnavljanje spomenutog izlučenog heterolognog imunoglobulina iz medija za uzgoj i time stvaranje heterolognog imunoglobulina u CHO stanici, koji se izlučuje u medij za uzgoj, pri čemu se prvi, drugi i treći vektor za transfekciju razlikuju samo u nukleinskoj kiselini koja prenosi otpornost na spomenuti prvi, drugi i treći eukariotski selekcijski agens.
The method according to any one of claim 1 to 17 and 19 to 21, characterized in that the method is suited for the production of a secreted heterologous immunoglobulin in large scale. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 17 i 19 do 21, naznačen time, da je postupak pogodan za proizvodnju izlučenog heterolognog imunoglobulina u velikom opsegu.
The method according to any one of claim 1 to 17 and 19 to 22, characterized in that cultivation is performed at a volume of at least 100 1, more preferably of at least 500 1, most preferably of at least 1000 1. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 17 i 19 do 22, naznačen time, da se kultivacija izvodi pri volumenu od najmanje 100 l, poželjnije najmanje 500 l, najpoželjnije najmanje 1000 l.
The method according to any one of claim 1 to 17 and 19 to 27, characterized in that the medium used in the cultivation is a serum-free medium, or a serum-free medium supplemented with defined mammal-derived components, or an animal-derived component free medium, or a protein-free medium, a protein-free medium supplemented with defined animal-derived components, or a chemically defined medium, or a mammal-derived component free medium, or a defined protein-free medium. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 17 i 19 do 27, naznačen time, da je medij korišten u kultivaciji medij bez seruma, ili medij bez seruma dopunjen definiranim komponentama dobivenih iz sisavaca, ili medij bez komponenti životinjskog porijekla, ili medij bez proteina, ili medij bez proteina dopunjen definiranim komponentama životinjskog porijekla, ili kemijski definirani medij, ili medij bez komponenti dobivenih od sisavaca, ili definirani medij bez proteina.
and R8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain 1 to 3 heteroatoms or groups independently selected from N, C(O), O and S(O)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R7 and R8 can be unsubstituted or substituted with 1 to 3 groups independently selected from amino, hydroxy, methoxy, halo, methyl, amino-methyl, methyl-amino and isobutyryloxy; or a pharmaceutically acceptable salt thereof. 
i R8 zajedno s atomom ugljika na kojega su oba priključeni, tvore 3-člani do 7-člani zasićeni ili djelomično nezasićeni prsten koji može opcionalno sadržavati od 1 do 3 heteroatoma ili skupina koji su neovisno odabrani od N, C(O), O i S(O)m; gdje je m odabran od 0, 1 i 2; dok navedeni zasićeni prsten koji je stvoren preko R7 i R8, može biti nesupstituiran ili supstituiran s 1 do 3 skupine koje su neovisno odabrane od sljedećih: amino, hidroksi, metoksi, halo, metil, metil-amino i izobutiriloksi; ili njegova farmaceutski prihvatljiva sol.
The compound of claim 2 in which R7 and R8 together with the carbon atom to which they are both attached form a 5 member saturated or partially unsaturated ring that can optionally contain 1 to 2 heteroatoms or groups independently selected from N, O, C(O) and S(O)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R7 and R8 is substituted with 1 to 3 groups independently selected from amino, hydroxy, methoxy, halo, methyl, methyl-amino and isobutyryloxy; or a pharmaceutically acceptable salt thereof. 
i R8 zajedno s atomom ugljika na kojega su oba priključeni, tvore 5-člani zasićeni ili djelomično nezasićeni prsten koji može opcionalno sadržavati 1 do 2 heteroatoma ili skupine koje su neovisno odabrane od N, O, C(O) i S(O)m; gdje je m odabran od 0, 1 i 2; dok je navedeni zasićeni prsten koji je stvoren preko R7 i R8, supstituiran s 1 do 3 skupine neovisno odabrane od sljedećih: amino, hidroksi, metoksi, halo, metil, metil-amino i izobutiriloksi, ili
The compound of claim 2 in which R7 and R8 together with the carbon atom to which they are both attached form a 6 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O and S(O)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R7 and R8 is substituted with amino; or a pharmaceutically acceptable salt thereof. 
i R8 zajedno s atomom ugljika na kojega su oba priključeni, tvore 6-člani zasićeni ili djelomično nezasićeni prsten koji može opcionalno sadržavati heteroatom odabran od N, O i S(O)m; dok je m odabran od 0, 1 i 2; pri čemu je navedeni zasićeni prsten koji je stvoren preko R7 i R8, supstituiran sa skupinom odabranom od sljedećih: amino, amino-metil i metil-amino, ili
The compound of claim 2 in which R7 and R8 together with the carbon atom to which they are both attached form a 4 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O and S(O)m; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R7 and R8 is substituted with a group selected from amino, amino-methyl and methyl-amino; or a pharmaceutically acceptable salt thereof. 
i R8 zajedno s atomom ugljika na kojega su oba priključeni, tvore 4-člani zasićeni ili djelomično nezasićeni prsten koji može opcionalno sadržavati heteroatom odabran od N, O i S(O)m; gdje je m odabran od 0, 1 i 2; pri čemu je navedeni zasićeni prsten koji je stvoren preko R7 i R8, supstituiran sa skupinom odabranom od sljedećih: amino, amino-metil i metil-amino;
2b) povidone, dextrane, polyethylene glycol, carboxymethyl cellulose or poly(vinyl-alcohol) in an amount of 0.2 to 10.0% by weight, 
povidon, dekstran, polietilen glikol, karboksimetilceluloza ili poli(vinil alkohol) u količini od 0,2 do 10,0 % masenog udjela,
The gel according to claims 1 to 3, characterized in that the amount of bimatoprost is less than 0.01 % by weight, preferably less than 0.0045 % by weight. 
Gel temeljem zahtjeva 1 do 3, naznačen time da je količina bimatoprosta manja od 0,01 % masenog udjela, poželjno manja od 0,0045 % masenog udjela.